Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Dr Gurdeep Mannu from the Nuffield Department of Population Health has won the Office for National Statistics (ONS) Research Excellence Award for a study which highlighted early risk factors for breast cancer patients.

breast examination

The study looked at more than 25 years of data on women receiving different breast cancer treatments, has been recognised by the ONS in its Research Excellence Awards for its insight and its important implications for management of patients with this kind of early-stage breast cancer in the future.   

Dr Gurdeep Mannu’s research showed that women who are diagnosed with ductal carcinoma in situ (an early-stage breast cancer) during breast screening go on to experience higher risks of developing invasive breast cancer and of death from breast cancer, compared with the general population. 

The research looked at data on 35,000 women in England diagnosed as having ductal carcinoma in situ by the NHS Breast Screening Programme from 1988 to 2014. It combined ONS mortality data with Hospital Episode Statistics from NHS Digital to show that the rate of women later developing invasive breast cancer was more than double what was expected, while mortality rates were 70% higher than expected. 

These findings will have important implications for management of patients with this kind of early-stage breast cancer in the future. 

The full story is on the Nuffield Department of Population Health website

Similar stories

Oxford vaccine reaches one billion doses released

The University of Oxford’s and our partners AstraZeneca have today announced that one billion doses of the ChAdOx1 nCov-19 coronavirus vaccine have been released, to more than 170 countries, marking a key milestone as part of the University and AstraZeneca’s joint vision to make the available to the world, on a not-for-profit basis for the world during the pandemic, and in perpetuity for low- and middle-income countries.

Research programme tackling COVID-19 variants of concern receives funding boost

A gift from the Red Avenue Foundation will enable the expansion of a major research programme aimed at rapidly identifying and interrogating emerging COVID-19 variants.

Phase I trial begins of new vaccine against the Plague

Researchers at the University of Oxford today launched a Phase 1 trial to test a new vaccine against plague.

New therapeutic targets identified in the treatment of psoriatic arthritis

Researchers identify two inflammatory-driving proteins, osteopontin and CCL2, highly expressed in psoriatic arthritis joints.

Treatment choice for rotator cuff disorders could create efficiency and savings for the NHS

A trial that evaluated the clinical and cost effectiveness of physiotherapy treatments for rotator cuff disorders suggests cost savings can be made while maintaining positive patient outcomes.